projects/dosespro
● Health & Fitness#3520 BY REVENUE
DosesPro

DosesPro

IN· via revenuecat
$143
Revenue · 30d
$241
Total lifetime
$2K
Est. ARR
—Revenue trend
JUN 19
start
JUN 22
JUN 29
unchanged
JUL 6
▲ 539.7%
JUL 13
unchanged
JUL 20
unchanged
JUL 27
next
▲no change recorded across the last 3 snapshots · figure may be stale at the source
https://dosespro.com
DosesPro
✓REVENUE VERIFIED
—Top ranked
—

About DosesPro

DosesPro is a GLP-1 medication tracking app designed for users of Mounjaro, Ozempic, Wegovy, and Zepbound. The app provides features such as smart injection tracking, weight analytics, AI-powered predictions, and professional reports to help users manage their medication journey effectively. It allows users to visualize their progress, stay informed with AI insights, and receive reminders for medication doses, making it a comprehensive toolkit for achieving weight loss goals.

Notable features include injection site tracking, missed dose tracking, and the ability to log symptoms for pattern an…

VibeCrowd AI
Investment companion
AI analysis
DosesPro is a revenue-stage, India-based support tool for GLP‑1 weight-loss therapy generating $143 in the last 30 days with $105 MRR and 0% growth.

The business shows real commercial validation — paying customers and recurring revenue — but the absolute scale is small today: $143 last-30-day receipts and $105 in recurring revenue. Zero 30-day growth (0%) is the most telling signal: acquisition or retention levers aren’t producing momentum yet. The product’s tight focus on Mounjaro, Ozempic, Wegovy and similar therapies is a strength for specialization but ties the business to the pace of GLP‑1 adoption and clinical/regulatory flows in its market.

— Strengths

Revenue-stage with paying customers and $105 in MRR, showing monetization exists
Clear niche: dedicated support for GLP‑1 weight-loss therapies — easier to message to prescribers and patients
Low absolute revenue means early-stage flexibility to iterate the product and pricing

— What to watch

Flat short-term growth (0%) suggests customer acquisition or retention needs attention
Small top-line ($143) limits how quickly the team can scale without additional investment or a big improvement in unit economics
Dependency on the GLP‑1 treatment market: uptake, prescribing patterns, and regulation will materially affect demand

◆ Best suited for

›Weight-loss clinics or telehealth providers offering GLP‑1 treatments that need patient support and adherence tools
›Founders building early-stage, vertical health‑SaaS in markets with expanding GLP‑1 use
›Clinicians or care networks looking to add a patient-facing adherence and education layer for semaglutide/Tirzepatide patients

A judgment from project data — not a user review.

Generated by VibeCrowd AI from on-platform data·not financial advice·Jul 2026
—

Rankings by revenue

No reviews yet
Used DosesPro? Be the first to share an honest review and help others decide.
No questions yet
Curious about pricing, features, or fit? Ask the first question.
—More in Health & Fitness
A
Anonymous startup
Health & Fitness$210K/mo
CalBuddy
CalBuddy
Health & Fitness$62K/mo
GoTall
GoTall
Health & Fitness$52K/mo
Taller
Taller
Health & Fitness$46K/mo
A
Anonymous startup
Health & Fitness$32K/mo
Pasul.ro
Pasul.ro
Health & Fitness$20K/mo